5-alpha-reductase deficiency pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology | [[Category:Endocrinology]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] |
Revision as of 19:48, 19 September 2012
5-alpha-reductase deficiency Microchapters |
Differentiating 5-alpha-reductase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
5-alpha-reductase deficiency pathophysiology On the Web |
American Roentgen Ray Society Images of 5-alpha-reductase deficiency pathophysiology |
Directions to Hospitals Treating 5-alpha-reductase deficiency |
Risk calculators and risk factors for 5-alpha-reductase deficiency pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pathophysiology
5-alpha-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT) in peripheral tissues. 5-alpha-reductase deficiency-2 is biochemically characterized by low to low normal levels of testosterone and decreased levels of 5α-DHT, creating a higher testosterone/DHT ratio.
DHT is a potent androgen, necessary for the development of male external genitalia in utero.